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Introduction: Idiopathic bronchiectasis is a poorly defined disease characterised by persistent
inflammation, infection and progressive lung damage. Natural killer (NK) cells provide a major
defense against infection, through the interaction of their surface receptors, including the
activating and inhibitory killer immunoglobulin-like receptors (KIR), and human leukocyte an-
tigens (HLA) class I molecules. Homozygosity for HLA-C has been shown in a single study to
confer increased genetic susceptibility to idiopathic bronchiectasis. We aimed to assess
whether the KIR and HLA repertoire, alone or in combination, may influence the risk of devel-
oping idiopathic bronchiectasis, in an independent replication study.
Methods: In this prospective, observational, case-control association study, 79 idiopathic bron-
chiectasis patients diagnosed following extensive aetiological investigation were compared
with 98 anonymous, healthy, age, sex and ethnically-matched controls attending blood donorersity Hospitals, Department of Respiratory Medicine, Newcastle Road, Galway, Ireland. Tel.: þ353
mail.com (M.J. McDonnell).
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dardised techniques. Determination of presence or absence of KIR genes was performed by a
sequence specific oligonucleotide probe method. Allele frequencies for the proposed KIR, HLA-
B and HLA-C risk alleles both individually and in combinations were compared.
Results: We found no significant differences in allele frequency between the idiopathic bron-
chiectasis and control samples, whether considering HLA-C group homozygosity alone or in
combination with the KIR type.
Discussion: Our results do not show an association between HLA-C and KIR and therefore do not
confirm previous positive findings. This may be explained by the lower frequency of HLA-C1
group homozygosity in the control population of the previous study (27.2%), compared to
42.3% in our study, which is consistent with the genetic profiling of control groups across the
UK. The previous positive association study may therefore have been driven by an anomalous
control group. Further larger prospective multicentre replication studies are needed to deter-
mine if an association exists.
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Bronchiectasis encompasses a large group of conditions
that share pathological dilatation of the bronchi as a
consequence of repeated, vicious cycles of infection and
inflammation [1]. There is growing awareness of the
importance of phenotyping bronchiectasis patients in order
to identify modifiable risk factors and to engage these pa-
tients in holistic disease management programs [2]. Up to
50% of patients, however, have no defined aetiology for
their bronchiectasis and are deemed idiopathic [1,2].
Although evidence clearly indicates a dysregulated immune
response in the pathogenesis of bronchiectasis, the patho-
physiology of idiopathic bronchiectasis remains poorly
elucidated, often resulting in a palliative, untargeted
approach to treatment. Previous immunogenetic studies of
idiopathic bronchiectasis have demonstrated defects in
both innate and adaptive immunity [3e5]. Such patients
appear to have shared clinical and radiological features,
suggesting a potential interplay between immunogenetic
susceptibility, immune dysregulation and chronic bacterial
infection [6].
Natural killer (NK) cells are a potent, rapid part of innate
immunity to infection and a link to priming of adaptive
immunity [7]. NK cells play an important role in the normal
functioning of lung host defence through the interaction of
their receptors, Killer cell Immunoglobulin-like Receptors
(KIR’s), with major histocompatibility complex (MHC) class I
molecules on target cells [8]. KIR’s are cell surface re-
ceptors that are polymorphic in both structure and func-
tion, with both activating and inhibitory receptor types
being expressed on an NK cell [8,9]. KIRs exhibit substantial
diversity at both the allelic and haplotypic levels resulting
in significant variation in susceptibility to pathogens and
disease.
The KIR proteins are members of the immunoglobulin
(Ig) superfamily of receptors. Their nomenclature is based
on their structure, where the number of Ig-like
KIR and HLA-C in idiopathic bronchiectasis 1129extracellular domains (2D or 3D) and the length of the
cytoplasmic tail (long, L or short, S) defines the name of the
protein [10]. The genes encoding the KIR molecules map in
a cluster (19q13.4) that contains all the genes for both
activating and inhibitory molecules [7]. KIR haplotypes can
broadly be classified as group A or B. The B group of hap-
lotypes are defined by the presence of one or more of the
following genes: KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS3,
KIR2DS5, and KIR3DS1. Conversely, the group A haplotypes
are defined by the absence of all of these genes and the
presence of KIR2DS4, the only activating gene in this group.
KIR2DS4 has a null allele which has a population frequency
of approximately 84%, thus a large proportion of individuals
homozygous for haplotype A may express no activating KIR
[11].
KIR genes encode receptors that differ in specificity for
HLA class I ligands and signalling potential. Well recognised
are the specificities of KIR2DL1, 2DL2, 2DL3 and KIR2DS1
and 2DS2 for HLA-C, KIR3DL1 for HLA-B, and KIR3DL2 for
HLA-A [10e12]. Both KIR and HLA loci show extreme pop-
ulation diversity and rapid evolution, suggesting that they
are under pathogen-mediated selection and that they in-
fluence disease outcome at the individual level.
When considering HLA-C molecules as ligands for KIR
receptors on NK cells, all HLA-C allotypes can be grouped
into two major KIR epitopes on the basis of a dimorphism at
position 80 of the a1 domain: asparagine defining HLA-C
group 1 and lysine defining HLA-C group 2 alleles. Group 1
alleles bind inhibitory KIRs 2DL2 and 2DL3 and activating
KIR2DS2, and group 2 alleles bind inhibitory KIR2DL1 and
activating KIR2DS1 [8e11]. KIR3DL1 recognises HLA-B al-
leles with the Bw4 serological motif (HLA-Bw4), with those
with an isoleucine at position 80 (Bw4I) showing stronger
inhibition than those with a threonine at this position
(Bw4T) [12]. An individual can be homozygous for Bw4T or
Bw4I or carry a single copy, heterozygous and carry both, or
negative for both. Certain combinations of HLA-C with
activating KIRs 2DS1 and 2DS2 have been shown to correlate
with autoimmune conditions, leukaemia and inflammatory
diseases [4,13e16]. Furthermore, high expression of the
highly inhibitory KIR3DL1 associated with HLA-B, along with
Bw4-80I ligands, has been shown to correlate with reduced
viral loads and slower rate of disease progression in human
immunodeficiency virus [17].
Through the interaction with KIRs, HLA-B and C mole-
cules are able to modulate NK-cell function. It has been
proposed that binding of HLA-C to activating KIR molecules
is ‘weaker’ than that to inhibitory KIR’s, favouring NK cell
inhibition in normal circumstances. Infected or diseased
cells with abnormal MHC class I expression fail to inhibit NK
activity and become targets of NK cell lytic activity [8]. This
ligand-receptor pairing is thus unusual in the immune sys-
tem in-so-far as inheritance of different combinations of
these polymorphic germ line sequences in populations im-
parts differential connectivity to NK-cell activation, with
different effector cell outcomes capable of exerting a
strong impact on disease susceptibility.
A previous UK study on 96 patients with idiopathic
bronchiectasis represents the only publication to date
examining the association between KIR and HLA-C type and
susceptibility to idiopathic bronchiectasis [4]. This com-
parison of patients with a similar number of normalcontrols, concluded that homozygosity for HLA-C group
type was associated with increased prevalence of idio-
pathic bronchiectasis. It was suggested that this homozy-
gosity might result in increased probability of mismatches
between KIR and HLA-C ligand with the potential to alter NK
cell regulation and function, representing a biologically
plausible genetic basis for disease predisposition. However,
replication studies to confirm or refute this finding have not
been performed. Confirmation of this association in a sec-
ond independent study would potentially lead to a signifi-
cant contribution to understanding the pathogenesis of
idiopathic bronchiectasis. We have therefore conducted a
study interrogating the same candidate gene poly-
morphisms in a separate population of rigorously pheno-
typed idiopathic bronchiectasis patients and controls,
matched according to age, gender, ethnicity and
geographical location to reduce confounding. This study is
of near identical size to the original study, employing
similar well-tested technology, comparing allele and ge-
notype frequencies for possible associations with KIR, HLA-
B and HLA-C risk alleles both individually and in
combinations.Methods
Study design
This regional observational, case-control association study
was performed prospectively over a two-year period
(October 2006 to August 2008). Ethical approval was ob-
tained from the regional ethics committee. Written
informed consent was obtained for all participants.
Reporting of this observational study conforms to the rec-
ommendations of STROBE [18].Study population
Our study population consisted of 79 consecutive unrelated
patients referred from primary care to two secondary care
bronchiectasis clinics in the North East of England at North
Tyneside General Hospital and the Freeman Hospital. The
consecutive study design meant that both new patients and
established clinic attendees were included. Inclusion
criteria consisted of adult Caucasian patients, aged 18
years or more, with a confirmed diagnosis of idiopathic
bronchiectasis after completion of relevant investigations.
Patients with traction bronchiectasis related to interstitial
lung disease were excluded. Given the heterogeneity sur-
rounding the aetiology of bronchiectasis, a comprehensive
clinical evaluation using history, examination and extensive
laboratory investigations with a detailed phenotyping pro-
tocol as previously published was performed to distinguish
patients with idiopathic bronchiectasis from patients with
bronchiectasis of known cause [2]. Patients with bronchi-
ectasis secondary to other causes such as congenital dis-
ease, post-infectious aetiology including mycobacterial
disease, chronic obstructive pulmonary disease, bronchial
asthma, connective tissue disorders, interstitial lung dis-
ease, cystic fibrosis, allergic bronchopulmonary aspergil-
losis, inhalational lung injury, gastro-oesophageal reflux,
Table 1 Baseline demographics and clinical characteris-
tics of idiopathic bronchiectasis patients.
Baseline characteristics Idiopathic
bronchiectasis
n (%) 79
Age, yr (SD) 65.3 (12.2)
Female, n (%) 39 (49.4)
>10 Pack year smoking
history, n (%)
16 (20.2)
FEV1%, mean (SD) 78.0 (25.6)
FVC%, mean (SD) 87.5 (20.7)
Ratio %, mean (SD) 70.7 (10.9)
HRCT total score,
mean (SD)
13.0 (10.2)
Sputum volume, ml,
mean (SD)
34.4 (53.5)
Chronic pseudomonas
colonisation, n (%)
12 (15.2)
Exacerbation frequency/
year, mean (SD)
4.44 (3.84)
Table 2 Idiopathic bronchiectasis screening investigations.
Full blood picture including serum eosinophil count
Serum IgG, IgA, IgM, IgG subclasses
Serum IgE
Alpha-1-antitrypsin level
Aspergillus precipitinsa
Rheumatoid factor
Anti-nuclear antibodies
Antibodies to haemophilus influenza B and pneumococcus
Cystic fibrosis genotyping and/or sweat testb
Screening for primary ciliary dyskinesia if indicated
Sputum for culture and sensitivity, smear and culture for
AFB
a Aspergillus skin prick test was performed if elevated
eosinophil count, IgE level or positive Aspergillus precipitins.
b 63 (80%) Patients underwent screening for cystic fibrosis.
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excluded.
Control population
The control subjects consisted of 98 anonymous, healthy
age gender and ethnically-matched blood donors from the
same geographical region (Newcastle upon Tyne, UK).
These samples were obtained from an anonymised histori-
cal archive of DNA samples from the academic haematology
laboratory at Newcastle University where uniform written
consent had already been granted for use in this and other
studies. No specific respiratory history or lung function re-
sults were available from the donors.
HLA-C and KIR gene analysis
Genomic DNA was derived from buccal samples (mouth-
wash) or whole blood by conventional means (SDS lysis,
proteinase K digestion, phenol and chloroform extraction,
ethanol precipitation in the presence of ammonium ace-
tate). Determination of the presence or absence of KIR
genes was performed by a sequence specific oligonucleo-
tide probe method (SSOP) [15,19,20]. Controls and patients
were classified as to whether they were positive for C1 or
C2 groups of HLA-C, HLA-B or both, and HLA-Bw4 (Bw4T or
Bw4I), or both. The presence of HLA-C1 group, -C2 group
and e Bw4 was also determined by the SSOP method. For
purposes of this study the HLA-Bw4 motif was only consid-
ered on the HLA-B locus. Typing for the presence or
absence of multiple activating and inhibitory KIR genes was
performed.
Statistical analysis
Allele and genotype frequency was determined by direct
counting. Statistical comparison between allele and geno-
typic frequencies in the study and control groups was per-
formed using chi square or Fisher’s exact test using SPSS
statistical software. p values less than or equal to 0.05 were
considered statistically significant.
Results
A diagnosis of idiopathic bronchiectasis was made in 79
consecutive bronchiectasis patients following careful
exclusion of other known causes of bronchiectasis. The
mean age of the patients was 65 years (12.2) with 40 (51%)
males and 39 (49%) females. 16 (20%) had a significant
smoking history of greater than 10 pack years. Mean FEV1%
was 78.0 (25.6). 12 (15%) were chronically colonised with
Pseudomonas aeruginosa. Table 1 shows the baseline de-
mographics of idiopathic bronchiectasis patients. A
comprehensive list of aetiological screening investigations
performed is included in Table 2.
HLA-C group 1 was present in 70 (89%) of idiopathic
bronchiectasis patients compared to 85 (87%) controls
(p Z 0.82). There was no difference in homozygosity for
HLA-C group 1 in idiopathic bronchiectasis patients
compared with controls. Comparison of HLA-C group 1 and 2alleles, whether alone or in combination, demonstrated no
statistical differences between the two patient groups (all
p > 0.05) (Table 3).
Inhibitory KIRs known to be associated with HLA-C
include KIR2DL1, 2DL2, 2DL3 and KIR2DS1 and 2DS2. Inter-
rogation of inhibitory KIRs, both alone and in combination
with HLA-C, demonstrated no statistical differences be-
tween idiopathic bronchiectasis patients and healthy con-
trols (Table 4).
Activating KIRS known to be associated with HLA-C
include 2DS1and 2DS2, neither of which were shown to be
more prevalent in patients with idiopathic bronchiectasis
compared to healthy controls (Table 5).
HLA-Bw4 alleles were present in 42 (54%) of idiopathic
bronchiectasis patients compared to 55 (56%) controls
(p Z 0.76) (Table 6). Consideration of the allelic groups of
Bw4 revealed no significant differences in homozygosity for
HLA-Bw4 in idiopathic bronchiectasis patients compared
with controls and no differences between the groups in
Table 3 Frequency of HLA-C alleles in idiopathic bron-
chiectasis patients and healthy controls.
HLA-C type Bronchiectasis
n Z 79
Controls n Z 98
n þve % þve n þve % þve
C1 70 89.7 85 86.7
C1 Homozygous 33 42.3 41 41.8
C2 45 57.7 57 58.2
C2 Homozygous 8 10.3 13 13.3
C1C2 37 47.4 44 44.9
Statistical comparison between genotypic frequencies in the
study and control groups was performed using chi square or
Fisher’s exact test using SPSS statistical software. All p-values
were >0.05 and were therefore not statistically significant.
Table 5 Frequency of activating KIRs in idiopathic bron-
chiectasis patients and healthy controls.
Activating KIRs
HLA-C
Bronchiectasis n
Z 79
Controls n Z 98
n þve % þve n þve % þve
2DS1 35 44.3 33 33.7
2DS2 46 58.2 57 58.2
2DS3 24 30.4 26 26.5
2DS4 75 94 94 95.9
2DS4 non-del 30 38 37 37.8
2DS4 del 59 74.7 79 80.6
2DS5 32 40.5 29 29.6
Statistical comparison between genotypic frequencies in the
study and control groups was performed using chi square or
Fisher’s exact test using SPSS statistical software. All p-values
were >0.05 and were therefore not statistically significant.
Table 6 Frequency of HLA-B alleles in idiopathic bron-
chiectasis patients and healthy controls.
HLA-B type Bronchiectasis
n Z 79
Controls n Z 98
n þve % þve n þve % þve
Bw4 42 53.9 55 56.1
Bw4 Homozygous 12 15.4 14 14.3
Bw4T 34 43.6 39 39.8
Bw4I 15 19.2 26 26.5
3DL1 75 94 94 95.9
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respectively.
The overall KIR frequency in activating and inhibitory
KIRs was not significantly different in patients with idio-
pathic bronchiectasis compared with control subjects
whether considering HLA-C group homozygosity alone or in
combination with the KIR type or HLA-B group homozygosity
alone or in combination with the KIR type. Proposed
inhibitory gene combinations of KIR and HLA-C or HLA-B
were found at essentially the same frequency in both
groups.
Discussion
Bronchiectasis results from a complex interplay between
lung infection and immunity, encompassing facets both of
host responsiveness to respiratory bacteria and of inflam-
matory immunopathogenesis. NK cells play a critical role at
the innateeadaptive interface during lung infection, and
are implicated in immunity to many of the key pathogens
implicated in the respiratory infections of these patients
[21,22]. Genotypic analysis of HLA-C and KIR has been used
across a wide range of infectious, inflammatory, autoim-
mune and malignant disease phenotypes to elucidate the
potential contribution of NK cell activation programmes in
disease susceptibility. Depending on the inheritance of
predominantly activating or inhibitory KIR genomicTable 4 Frequency of HLA-C inhibitory KIRs in idiopathic
bronchiectasis patients and healthy controls.
Inhibitory KIRs HLA-C Bronchiectasis
n Z 79
Controls n Z 98
n þve % þve n þ ve % þve
2DL1 with C2 43 54.4 52 53.1
2DL1 without C2 32 40.5 40 40.8
2DL2 with C1 40 50.6 51 52
2DL2 without C1 6 7.6 6 6.1
2DL3 with C1 63 79.7 77 78.6
2DL3 without C1 5 6.3 12 12.2
Statistical comparison between genotypic frequencies in the
study and control groups was performed using chi square or
Fisher’s exact test using SPSS statistical software. All p-values
were >0.05 and were therefore not statistically significant.repertoires and on differential inheritance of the cognate
HLA-C class I ligands, humans may have an inherent po-
tential for NK cell activation ranged across a spectrum of
activation [23]. Susceptibility to viral infection, has tended
to be associated with inhibitory genotypes, while suscep-
tibility to autoimmune, inflammatory and neoplastic pa-
thology is often associated with activating genotypes.
Studies analysing potential susceptibility factors for
idiopathic bronchiectasis are scarce. The above mentioned
UK study performed several years ago demonstrated a po-
tential genetic susceptibility in idiopathic bronchiectasis
with significantly increased frequency of HLA-C1 homozy-
gosity in idiopathic bronchiectasis patients compared to3DL1 with Bw4 41 52.6 53 54.1
3DL1 without Bw4 33 42.3 41 41.8
3DL1 with Bw4T 34 44.2 38 38.8
3DL1 without Bw4T 38 49.4 56 57.1
3DL1 with Bw4I 13 16.9 24 24.5
3DL1 without Bw4I 62 80.5 70 71.4
3DS1 37 46.8 33 33.7
3DS1 with Bw4 19 24.4 20 20.4
3DS1 without Bw4 16 20.5 13 13.3
3DS1 with Bw4T 14 18 10 10.2
3DS1 without Bw4T 21 26.9 23 23.5
3DS1 with Bw4I 9 11.5 12 12.2
3DS1 without Bw4I 25 32 21 21.4
Statistical comparison between genotypic frequencies in the
study and control groups was performed using chi square or
Fisher’s exact test using SPSS statistical software. All p-values
were >0.05 and were therefore not statistically significant.
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articles [6]. They concluded that approximately 50% of
their idiopathic bronchiectasis cohort was HLA-C group 1
homozygous, compared with 25% of controls. The Cw*03
allele was reported to carry a 2$27-fold increased suscep-
tibility risk and the Cw*06 allele a 0$26-fold reduced risk
[4].
Our results do not confirm any of the previous findings. In
our study, there was no difference in homozygosity for HLA-
C group 1 and no significant difference between expression
of activating KIRs and HLA-C groups alone or in combina-
tion, in idiopathic bronchiectasis patients compared with
controls. It is interesting to note that the frequency of HLA-
C1 homozygosity in our patients are similar to the fre-
quency of the patients in the previous study with 42% in our
study and 49% in the previous study. The main difference,
therefore, seems to lie in the frequency of HLA-C1 homo-
zygosity in the control populations of the two studies; 42%
having HLA-C1 group homozygosity in the current study
whilst it was 27% in the previous study. The (unusally) lower
proportion of HLA-C1 homozygosity in the controls of the
previous study seems most likely to account for the previ-
ously observed positive association.
To try and account for the differences in control pop-
ulations between the two studies, we examined other
available UK data for comparison. The percentage of HLA-
C1 homozygosity in a Northern Ireland population (nZ 322)
was 48% and again, 48% in a population from the Orkney
Islands (n Z 68), consistent with that of our study. [23] We
also looked at the frequency of HLA-C1 group homozygosity
in the last 100 solid organ donors tissue typed at our centre:
49% were HLA-C1 homozygous, with 23% carrying HLA-
Cw03. This compares to 27% HLA-C1 homozygous in the
previous study, with 10% carrying HLA-Cw03. Furthermore
we examined data available on the worldwide web; www.
allelefrequencies.net of comparable English populations
[24]. Although this data did not make available HLA-C1
homozygosity frequencies, we were able to determine
that in data of blood donors taken at various UK centres,
the ratio of HLA-C1 group frequency to HLA-C2 group fre-
quency was 1.64 (Newcastle n Z 2739), 1.72 (Leeds
n Z 5024), 1.75 (Liverpool n Z 1343), 1.77 (Manchester
n Z 1640) and 1.79 (Lancaster n Z 545) [24]. However the
ratio in the original study of Boyton et al. was 0.95 in
controls compared to 1.92 in patients. The main differences
in frequencies of individuals with the HLA-Cw allele fam-
ilies between the Heart/Lung donors in the study by Boyton
et al. and the blood donors was in HLA-Cw03 e 10% in the
former compared to range of 23e28% in blood donors from
the various UK donation centres.
There are a number of other possible reasons why our
work differs from that of Boyton et al. Significant variation
between age and gender between the two study groups was
observed in the previous study (55  1.4 years; 32% male in
idiopathic bronchiectasis patients versus 24.8  1.4 year;
73% male in control patients), which may also have
contributed to the positive association found. Considerable
variation in the composition of KIR haplotypes with geog-
raphy and ethnicity has been noted. The significance of the
interesting observation that some populations, such as
aboriginal Australians who have very high prevalence of
bronchiectasis and have some of the most activating KIRhaplotypes has yet to be elucidated [25]. The difference
outlined between the two studies described may therefore
relate to geographical variations among control pop-
ulations, perhaps with population differences in the North
and the South of the UK. There is further diversity and
complexity due to the fact that different individuals within
a given population will carry different numbers of acti-
vating and inhibitory KIR genes and different polymorphic
variants of these genes [9]. Furthermore, the impact of the
KIR repertoires will vary depending on whether a given in-
dividual also carries the cognate HLA class I polymorphic
variant with which the KIRs interact. Finally, there is var-
iegated expression of KIR gene products, such that they are
differentially expressed on the NK cells (and T cells) within
each individual [6]. All of these factors are important
considerations and, although our study cannot conclude
with certainty that there is no obvious genetic suscepti-
bility towards the development of idiopathic bronchiec-
tasis, we have opened up the area to debate, likely
prompting further investigation into the pathophysiology of
this disease process to corroborate these findings.
Although precautions were taken to ensure as robust a
study design as possible, there remain a number of inherent
limitations to our study. Firstly our sample size is small; we
failed to recruit as many idiopathic bronchiectasis patients
as we initially estimated would be possible, reflecting the
stringent phenotyping protocol; this may raise the possibility
of a false negative result being obtained through under-
powering of the study. Despite this, however, our study is of
similar sample size and design to the previous study and is
therefore comparable. Secondly our patients were all of
Caucasian origin recruited from one area in the North East of
England potentially limiting the generalisability of our re-
sults to other worldwide populations. Genetic association
studies have progressed since these two studies were origi-
nally performed, but the similar sample and control sizes
should enable this study to serve as a standard replication
study in an independent patient cohort and may serve to
encourage topical debate, which can inform further, larger
studies. To date no large bronchiectasis genetic association
studies have been conducted due to funding difficulties.
Such studies with multicentre recruitment using standard-
ized phenotyping protocol are now recognised as a priority
[3,26]. This study recruited from two geographically close
centres and a challenge is now to extend such studies to in-
ternational multicentre studies.
In conclusion, we found no association between KIR and
HLA type B or C and idiopathic bronchiectasis. We suggest
the original report of this association was due to unusual
genotype frequencies in the control population that are
atypical as compared to other UK populations. Collectively
these data cannot provide a definitive assessment of KIR
and NK cell biology in bronchiectasis and we suggest
caution is warranted regarding conclusions that available
“immunogenetic analysis predicts a pathogenic role for
excessive NK cell activation in bronchiectasis” [2]. The
availability of techniques that factor in both polymorphic
KIR variability and copy number variability will add to the
usefulness and clinical application of these studies [9,27].
However, further larger prospective multi-centre replica-
tion studies to define the genetic risk factors associated
with idiopathic bronchiectasis are needed.
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